Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1 / BRCA2 mutation carriers

Lucie Bignon 1, * Jean-Pierre Fricker 1 Catherine Noguès 2 Emmanuelle Mouret-Fourme 2 Dominique Stoppa-Lyonnet 3, 4, 5, 6 Olivier Caron 7 Alain Lortholary 8 Laurence Faivre 9, 10 Christine Lasset 11 Veronique Mari 12 Paul Gesta 13 Laurence Gladieff 14 Akila Hamimi 15 Thierry Petit 16, 17 Michel Velten 17, 18
* Auteur correspondant
1 Département de médecine oncologique
2 CRLCC René Huguenin
3 Département de Biologie des Tumeurs
4 U830 - Unité de génétique et biologie des cancers
5 UPD5 - Université Paris Descartes - Paris 5
6 USPC - Université Sorbonne Paris Cité
7 Département de médecine oncologique [Gustave Roussy]
8 CCS - Centre Catherine-de-Sienne [Nantes]
9 UNICANCER/CRLCC-CGFL - Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon]
10 Centre de génétique - Centre de référence des maladies rares, anomalies du développement et syndromes malformatifs (CHU de Dijon)
11 Centre Léon Bérard [Lyon]
12 UNICANCER/CAL - Centre de Lutte contre le Cancer Antoine Lacassagne [Nice]
13 CH Georges Renon Niort - Centre Hospitalier Georges Renon [Niort]
14 Institut Claudius Regaud
15 Hôpital René HUGUENIN (Saint-Cloud)
16 Département d'Oncologie et Hématologie [Strasbourg]
17 CRLCC Paul Strauss
18 Progression tumorale et microenvironnement. Approches translationnelles et épidémiologie
Abstract : This study aims to estimate the pathologic complete response (pCR) rate after neo-adjuvant chemotherapy and to compare disease-free survival (DFS) and overall survival (OS) between pCR and non-pCR groups of patients with triple-negative breast cancer (TNBC) and deleterious BRCA1 or BRCA2 mutation. We carried out a retrospective analysis of 53 patients including 46 BRCA1, 6 BRCA2, and 1 combined BRCA1 and BRCA2 mutation. All patients had been diagnosed with triple-negative breast cancer (TNBC) between 1997 and 2014. Neo-adjuvant therapy consisted of regimens that were based on anthracycline or an anthracycline-taxane doublet. DFS included any relapse or second cancer. The Kaplan-Meier method and the log-rank test were used to compare pCR and non-pCR groups. A pCR was observed in 23 (42.6% [95% CI, 29.2%-56.8%]) of the TNBC included. The pCR rate was 38.3% [95% CI, 26%-55%] among BRCA1 mutation carriers, and 66% among the 6 BRCA2 mutation carriers. Median follow-up was 4.4 years (range 0.62-16.2 years) and did not differ between the groups (P = .25). Fifteen relapses and six second cancers were recorded during the follow-up period. Eleven deaths occurred, all of which were in the non-pCR group. DFS (P < .01) and OS (P < .01) were significantly better in the pCR group than the non-pCR group. This study shows a high pCR rate after neo-adjuvant therapy in BRCA-mutated triple-negative breast cancer, and the survival results confirm the prognostic value of pCR in this group. These outcomes should be considered as a basis of comparison to be used by future studies about new therapies in this domain.
Keywords : BRCA1 mutation BRCA2 mutation neo-adjuvant chemotherapy pathologic complete response prognostic significance triple-negative breast cancer
Type de document :
Article dans une revue
Liste complète des métadonnées
https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01960320
Contributeur : Lnc - Université de Bourgogne <>
Soumis le : mercredi 19 décembre 2018 - 12:43:49
Dernière modification le : mardi 21 juillet 2020 - 03:58:22

Identifiants

Collections

UNIV-BOURGOGNE | LNC-UMR866 | LNC-GAD | ICR | CGFL | CURIE | STRAUSS | HUGUENIN | FNCLCC | UNIV-PARIS5 | SITE-ALSACE | IGR | USPC | UNIV-PARIS-SACLAY | UNIV-PARIS | PSL

Citation

Lucie Bignon, Jean-Pierre Fricker, Catherine Noguès, Emmanuelle Mouret-Fourme, Dominique Stoppa-Lyonnet, et al.. Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1 / BRCA2 mutation carriers. The Breast Journal, 2018, 24 (3), pp.269-277. ⟨10.1111/tbj.12887⟩. ⟨hal-01960320⟩

Exporter

BibTeX TEI DC DCterms EndNote

Partager

Métriques

Consultations de la notice

426